ライフサイエンスコーパス: be noninferior to

1 zolid (200 mg once daily) has been proven to be noninferior to 10 days of linezolid (600 mg twice dai

2 tedizolid phosphate (plus 4 days of placebo) was noninferior to 10 days of 600-mg twice-daily oral li

3 d sinogram-affirmed iterative reconstruction was noninferior to 100% exposure (P = .002 and P < .001,

4 tents, 3 months of dual antiplatelet therapy was noninferior to 12 months for NACCE, without signific

5 before day 7, an antibiotic course of 7 days was noninferior to 14 days.

6 -day treatment with systemic glucocorticoids was noninferior to 14-day treatment with regard to reexa

7 latelet treatment with DAPT for 6 months may be noninferior to 24-month DAPT in aspirin-sensitive pat

8 3D in women aged 15-25 years and 2D (M0,12) was noninferior to 2D (M0,6).

9 GMT ratios (cLIA) for both 2D and 3D girls were noninferior to 3 doses in women for HPV6/11/16/18.

10 After BEACOPPbaseline, 20 Gy IF-RT was noninferior to 30 Gy (10-year PFS, 84% v 84%; HR, 1.

11 V6/11/16/18 after 2D or 3D of 4vHPV in girls were noninferior to 3D in adult women up to 120 months p

12 e, both 2D regimens in girls aged 9-14 years were noninferior to 3D in women aged 15-25 years and 2D

13 12) elicited HPV-16/18 immune responses that were noninferior to 3D in women aged 15-25 years.

14 Our data suggest that (18)F-DCFPyL is noninferior to (68)Ga-PSMA-HBED-CC, while offering th

15 nclusion: Our data suggest that (18)F-DCFPyL is noninferior to (68)Ga-PSMA-HBED-CC, while offering th

16 A single 1200-mg dose of oritavancin was noninferior to 7-10 days of vancomycin in treating A

17 ong patients with CABP, 5-day oral lefamulin was noninferior to 7-day oral moxifloxacin with respect

18 hs of once-weekly rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone for preve

19 -month regimen of rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone for preve

20 resorbable scaffold has been demonstrated to be noninferior to a contemporary metallic drug-eluting s

21 mg per deciliter [2.0 mmol per liter]) would be noninferior to a traditional threshold (treatment at

22 A single 1500-mg infusion of dalbavancin is noninferior to a 2-dose regimen, has a similar safety

23 Conclusion Autologous blood patch injection is noninferior to a hydrogel plug regarding the rate of

24 to investigate whether the BioFreedom stent is noninferior to a modern ultrathin strut biodegradable

25 Dalbavancin delivered as a single dose was noninferior to a 2-dose regimen (81.4% vs 84.2%; dif

26 es with about 5 hours of therapeutic contact was noninferior to a conventional course of CBT that pro

27 bated within 24 hours, a lower PEEP strategy was noninferior to a higher PEEP strategy with regard to

28 tive strategy regarding red-cell transfusion was noninferior to a liberal strategy with respect to th

29 nolones and aminoglycosides, a short regimen was noninferior to a long regimen with respect to the pr

30 t regarding visual outcomes, the T&E regimen was noninferior to a monthly dosing regimen.

31 se treatment threshold (36 mg per deciliter) was noninferior to a traditional threshold (47 mg per de

32 eeks (98.9%) or 8 weeks (97.8%) of treatment were noninferior to a historical control (98%).

33 To investigate whether bevacizumab is noninferior to aflibercept for the treatment of macul

34 ge from baseline (letters) with brolucizumab was noninferior to aflibercept at week 12 (5.75 and 6.89

35 nal vein occlusion, intravitreal bevacizumab was noninferior to aflibercept with respect to visual ac

36 icardial, centrifugal-flow LVAD was found to be noninferior to an axial-flow LVAD with respect to sur

37 pothesis was that an INR target of 1.8 would be noninferior to an INR target of 2.5, using a noninfer

38 Whether a cardiovascular MRI-based strategy is noninferior to an FFR-based strategy with respect to

39 ts in Cameroon, a dolutegravir-based regimen was noninferior to an EFV400-based reference regimen wit

40 me, an iFR-guided revascularization strategy was noninferior to an FFR-guided revascularization strat

41 xtended prophylaxis for 28 days with aspirin was noninferior to and as safe as dalteparin for the pre

42 Antibiotics were noninferior to appendectomy on the basis of 30-day

43 r the treatment of appendicitis, antibiotics were noninferior to appendectomy on the basis of results

44 High-dose unilateral ECT was noninferior to bitemporal ECT regarding the 24-item

45 that forgoing bridging anticoagulation would be noninferior to bridging with low-molecular-weight hep

46 sessment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the

47 Trials concluding IAD is noninferior to CAD were based on wide NIMs that inclu

48 ks, monotherapy with once-daily dolutegravir was noninferior to cART.

49 Here, we evaluated whether TCC is noninferior to CBT-I for the treatment of insomnia in

50 Tests of noninferiority showed that TCC was noninferior to CBT-I at 15 months ( P = .02) and at

51 CCTA/rCTP is noninferior to CCTA/SPECT-MPI to discriminate ACS and

52 horacic echocardiography and lung ultrasound are noninferior to chest x-ray for screening of pneumoth

53 horacic echocardiography and lung ultrasound is noninferior to chest radiograph when used to accurate

54 care is not available leads to outcomes that are noninferior to CIC follow-up.

55 Etelcalcetide was noninferior to cinacalcet on the primary end point.

56 er mindfulness-based stress reduction (MBSR) is noninferior to cognitive behavioral therapy for insom

57 The short-course radiotherapy was noninferior to commonly used radiotherapy.

58 ositioned, continuous-flow, centrifugal pump was noninferior to contemporaneously implanted, commerci

59 ition, changing to oral antibiotic treatment was noninferior to continued intravenous antibiotic trea

60 aimed to determine whether oral antibiotics were noninferior to continued intravenous antibiotics fo

61 were to assess whether intermittent therapy was noninferior to continuous therapy with respect to su

62 ssant prescribing in the DEV and IMCP groups was noninferior to control (mean percentage point differ

63 ach trial, we tested whether dexmedetomidine was noninferior to control with respect to proportion of

64 EFA in all short-course arms was noninferior to control.

65 te symptomatic VTE, NOACs have been shown to be noninferior to conventional anticoagulant therapy for

66 ty and specificity of CellScope-based LED FM was noninferior to conventional LED FM by using a presel

67 Filtered sunlight was noninferior to conventional phototherapy for the tre

68 Apixaban was noninferior to conventional therapy (P<0.001) for pr

69 A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatmen

70 Nasal high-flow therapy was not shown to be noninferior to CPAP and resulted in a significantly h

71 ed to achieve noninferiority at 6 months but was noninferior to CPVI at 1 year in achieving freedom o

72 single procedure but, after redo procedures, was noninferior to CPVI at 12 months for freedom from AF

73 rdiopulmonary bypass, fibrinogen concentrate is noninferior to cryoprecipitate with regard to number

74 Rituximab was noninferior to cyclosporine in inducing complete or

75 ies and at both starting doses, peginesatide was noninferior to darbepoetin in increasing and maintai

76 ction of XG-102 at the end of ocular surgery is noninferior to dexamethasone eye drops in the treatme

77 anterior cell grades for both XG-102 groups were noninferior to dexamethasone (-0.054 anterior cell

78 To investigate whether distal diuretics are noninferior to dietary sodium restriction in reducin

79 Distal diuretics are noninferior to dietary sodium restriction in reducin

80 Self-administered therapy without reminders was noninferior to direct observation in the United Stat

81 stroke and increased risk of bleeding, LAAC was noninferior to DOAC in preventing major AF-related c

82 Pazopanib was noninferior to doxorubicin, rendering pazopanib a pu

83 II, SRK/T, Holladay 2, and Hoffer Q formulas were noninferior to each other.

84 atrial fibrillation, a wait-and-see approach was noninferior to early cardioversion in achieving a re

85 mpared these 2 stents and has shown that ZES was noninferior to EES at 12-month for the primary end p

86 e gene expression profiling (GEP) blood test was noninferior to EMB between 6 and 60 months post tran

87 Stenting was noninferior to endarterectomy with regard to the pri

88 gh risk for surgical complications, stenting was noninferior to endarterectomy with regard to the rat

89 Rivaroxaban may be noninferior to enoxaparin with regard to the preventi

90 riority was planned if rivaroxaban proved to be noninferior to enoxaparin.

91 In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thro

92 ERALD 1 and 725 from EMERALD 2, peginesatide was noninferior to epoetin in maintaining hemoglobin lev

93 ive Therapies) trial found triple therapy to be noninferior to etanercept-methotrexate in patients wi

94 pt and methotrexate, P=0.26); triple therapy was noninferior to etanercept and methotrexate, since th

95 nd hydroxychloroquine added to methotrexate, was noninferior to etanercept plus methotrexate in patie

96 paclitaxel-eluting stents were not shown to be noninferior to everolimus-eluting stents, and they re

97 d on a phase 3 trial, telaprevir twice daily is noninferior to every 8 hours in producing SVR12, with

98 nstruction at 25% and 50% exposure reduction was noninferior to FBP at 100% exposure (P </= .013).

99 is using mixed linear models showed that PBT was noninferior to FBT on all outcomes at 6-, 12-, and 1

100 Although withholding FDP was found to be noninferior to FDP for the study population as a whol

101 Withholding FDP was noninferior to FDP in holes </=400 mum in diameter.

102 We aimed to evaluate whether iFR is noninferior to FFR with respect to the rate of subseq

103 e of coronary revascularization than FFR and was noninferior to FFR with respect to major adverse car

104 Seroconversion with fIPV im was noninferior to fIPV id for all serotypes.

105 treatment duration and fixed 7-day treatment were noninferior to fixed 14-day treatment.

106 igh risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidenc

107 ring a mean follow-up of 2.3 years, Respimat was noninferior to HandiHaler with respect to the risk o

108 e daily after initial treatment with heparin was noninferior to high-quality standard therapy and cau

109 At moderate doses, celecoxib was found to be noninferior to ibuprofen or naproxen with regard to c

110 erm effectiveness of home-based HT with a CD is noninferior to iHT performed by therapists in pediatr

111 ment Therapy (ENCORE), at 1 year, eliglustat was noninferior to imiglucerase enzyme therapy in mainta

112 t the 1-year follow-up, telephone counseling was noninferior to in-person counseling for all psychoso

113 phone delivery of BRCA1/2 genetic counseling was noninferior to in-person delivery.

114 We hypothesized that external cardioversion is noninferior to internal cardioversion for safety, and

115 nagement of primary spontaneous pneumothorax was noninferior to interventional management, with a low

116 investigated whether oral antibiotic therapy is noninferior to intravenous antibiotic therapy for thi

117 treatment in bone and joint infection (BJI), is noninferior to intravenous therapy.

118 Oral antibiotic therapy was noninferior to intravenous antibiotic therapy when u

119 the hypothesis that intramuscular midazolam was noninferior to intravenous lorazepam by a margin of

120 Intravenous-to-oral solithromycin was noninferior to intravenous-to-oral moxifloxacin.

121 Oral antibiotics were noninferior to intravenous antibiotics for the earl

122 d to assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment

123 d to assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment

124 Intravitreal dexamethasone implant was noninferior to ITA at 8 weeks (PropBL IDI/PropBL ITA

125 In this randomized trial, POEM was noninferior to LHM plus Dor's fundoplication in cont

126 reat population, omadacycline (316 patients) was noninferior to linezolid (311 patients) with respect

127 Omadacycline was noninferior to linezolid for the treatment of acute

128 Omadacycline was noninferior to linezolid using the Food and Drug Adm

129 Omadacycline also was noninferior to linezolid with respect to investigato

130 imited evidence that the Watchman device may be noninferior to long-term OAC in selected patients.

131 >/=1, a left atrial appendage closure device is noninferior to long-term warfarin for stroke preventi

132 Sulfur hexafluoride gas was found to be noninferior to longer-acting gases (95% confidence in

133 Sulfur hexafluoride gas tamponade was noninferior to longer-acting gases in the surgical m

134 that femoral hemostasis achieved through VCD is noninferior to manual compression in terms of vascula

135 oing transfemoral coronary angiography, VCDs were noninferior to manual compression in terms of vascu

136 Pyronaridine-artesunate was noninferior to mefloquine plus artesunate for the pr

137 Miltefosine is noninferior to meglumine antimoniate for treatment of

138 Ceftazidime-avibactam plus metronidazole was noninferior to meropenem across all primary analysis

139 Once-daily plazomicin was noninferior to meropenem for the treatment of compli

140 th ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in adult patients with cIAI

141 Treatment with eravacycline was noninferior to meropenem in adult patients with cIAI

142 Ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in the primary (83.0% [323/

143 Eravacycline was noninferior to meropenem in the primary endpoint (17

144 Ceftazidime-avibactam plus metronidazole was noninferior to meropenem in the treatment of complic

145 Plazomicin was noninferior to meropenem with respect to the primary

146 Everolimus 1.5 mg was noninferior to MMF for this endpoint at month 12 (35

147 owance for as-needed ranibizumab injections, was noninferior to monthly ranibizumab as well as to as-

148 nd in eyes with PVD, and quarterly treatment was noninferior to monthly treatment (P = 0.001).

149 wed that zoledronic acid (ZA) every 3 months was noninferior to monthly ZA in reducing the risks of S

150 howed that monthly and bimonthly aflibercept were noninferior to monthly ranibizumab at preventing vi

151 Omadacycline was noninferior to moxifloxacin for early clinical respo

152 Lefamulin was noninferior to moxifloxacin for ECR (87.3% vs 90.2%,

153 Lefamulin was noninferior to moxifloxacin for the primary efficacy

154 Omadacycline was noninferior to moxifloxacin for the treatment of com

155 Omadacycline was noninferior to moxifloxacin, based on a new ECR endp

156 patient-controlled analgesia (IV-PCA) could be noninferior to multimodal thoracic epidural analgesia

157 Glycerol phenylbutyrate was noninferior to NaPBA with respect to ammonia control

158 The use of HHHFNC was noninferior to nCPAP with regard to the primary outc

159 test if high-flow conditioned oxygen therapy is noninferior to NIV for preventing postextubation resp

160 h ranibizumab resulted in visual acuity that was noninferior to (not worse than) PRP treatment at 2 y

161 and 10-mg daily doses of ulipristal acetate were noninferior to once-monthly leuprolide acetate in c

162 ectomy to date, and it demonstrates that RPD is noninferior to OPD in terms of pancreatic fistula dev

163 Laparoscopy was noninferior to open surgery for rectal cancer in ter

164 s demonstrated that high flow nasal cannulae are noninferior to or no better than CPAP when used to s

165 th long-acting cabotegravir plus rilpivirine was noninferior to oral therapy with dolutegravir-abacav

166 ed with sentinel lymph node dissection alone was noninferior to overall survival for those treated wi

167 ists, high-definition, white-light endoscopy is noninferior to pancolonic chromoendoscopy for detecti

168 rated that CNN-based diagnosis of SRH images was noninferior to pathologist-based interpretation of c

169 procedure, forgoing bridging anticoagulation was noninferior to perioperative bridging with low-molec

170 ngle-photon emission tomography was found to be noninferior to PET in terms of specificity (P < .001)

171 We hypothesized that semaglutide would be noninferior to placebo for the primary outcome.

172 The DPP4i sitagliptin has been shown to be noninferior to placebo with regard to primary and sec

173 rimary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary out

174 t exenatide, administered once weekly, would be noninferior to placebo with respect to safety and sup

175 nd increased cardiovascular risk, aclidinium was noninferior to placebo for risk of MACE over 3 years

176 Sitagliptin was noninferior to placebo for the primary composite car

177 erotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse

178 ng that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.0

179 To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1

180 Primary analyses examined whether 4F-PCC was noninferior to plasma for the coprimary end points o

181 PF-AES were noninferior to PP-ZES regarding target-lesion failu

182 5 mg in low-body-weight (LBW) patients would be noninferior to prasugrel 10 mg in higher-body-weight

183 Nepafenac was noninferior to prednisolone in controlling inflammat

184 Nepafenac was noninferior to prednisolone with regard to inflammat

185 laria, although tafenoquine was not shown to be noninferior to primaquine.

186 vant chemotherapy and interval cytoreduction are noninferior to primary cytoreduction and adjuvant ch

187 sachusetts without on-site surgical services were noninferior to procedures performed at hospitals wi

188 To determine whether yoga is noninferior to PT for cLBP.

189 manualized yoga program for nonspecific cLBP was noninferior to PT for function and pain.

190 BR was noninferior to R-CHOP/R-CVP, as assessed by the prim

191 al to determine whether cryoballoon ablation was noninferior to radiofrequency ablation in symptomati

192 this randomized trial, cryoballoon ablation was noninferior to radiofrequency ablation with respect

193 he change in visual acuity, that bevacizumab is noninferior to ranibizumab for patients with ME resul

194 In the per protocol analysis, bevacizumab was noninferior to ranibizumab (bevacizumab minus ranibi

195 Bevacizumab was noninferior to ranibizumab for visual acuity at 1 ye

196 Ranibizumab with laser was noninferior to ranibizumab monotherapy (mean average

197 ponses to routine vaccines given with 4CMenB were noninferior to routine vaccines alone for all antig

198 lower-dose FBP images without ANLM or SAFIRE were noninferior to routine-dose images for abdominal CT

199 COBI was noninferior to RTV in combination with ATV plus FTC/

200 TAVR was noninferior to SAVR when compared using both trial a

201 osbuvir-velpatasvir-voxilaprevir for 8 weeks was noninferior to sofosbuvir-velpatasvir for 12 weeks,

202 RT, as monotherapy or followed by sorafenib, is noninferior to sorafenib and to compare safety profil

203 on: SIRT as initial therapy for advanced HCC is noninferior to sorafenib in terms of OS and offers a

204 SIRT, whether or not followed by sorafenib, was noninferior to sorafenib (10.2 and 9.2 mo [hazard ra

205 Primary care management was noninferior to specialist management with a mean cha

206 us diethylcarbamazine plus albendazole [IDA] is noninferior to standard 3 annual doses of ivermectin

207 Low dose is noninferior to standard dose with respect to rate of

208 These data indicate BR is noninferior to standard therapy with regard to clinic

209 Micafungin was noninferior to standard care as antifungal prophylax

210 Rivaroxaban was noninferior to standard therapy (noninferiority marg

211 A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and

212 selection of oral P2Y(12) inhibitor therapy was noninferior to standard treatment with ticagrelor or

213 Drug-coated balloons were noninferior to standard balloons with respect to th

214 four sites in Italy tested whether rituximab is noninferior to steroids in maintaining remission in j

215 In conclusion, rituximab was noninferior to steroids for the treatment of juvenil

216 rical treatment with beta-lactam monotherapy was noninferior to strategies with a beta-lactam-macroli

217 Oral apixaban was noninferior to subcutaneous dalteparin for the treat

218 Oral edoxaban was noninferior to subcutaneous dalteparin with respect

219 Pazopanib was noninferior to sunitinib with respect to progression

220 a self-expanding supraannular bioprosthesis was noninferior to surgery with respect to the composite

221 l" strategy of left atrial appendage closure is noninferior to "systemic" anticoagulation with warfar

222 IV-PCA was noninferior to TEA for the treatment of postoperativ

223 , -4.9% to 12.0%), so telaprevir twice daily is noninferior to telaprevir every 8 hours.

224 The efficacy of tafenoquine was not shown to be noninferior to that of primaquine (odds ratio for rec

225 t material-enhanced computed tomography (CT) is noninferior to that of a traditional 13-hour oral reg

226 corneal donor tissue preserved 8 to 14 days is noninferior to that of donor tissue preserved 7 days

227 ithout axillary lymph node dissection (ALND) is noninferior to that of women treated with axillary di

228 ibody response to HPV-6, 11, 16, and 18 that was noninferior to that generated by the qHPV vaccine.

229 Sleep duration in flexible programs was noninferior to that in standard programs (between-gr

230 e trial year vs. 12.6% in the pretrial year) was noninferior to that in the standard programs (12.2%

231 e-day IOP-lowering efficacy of BAK-free TRAV was noninferior to that of BAK 0.02%-preserved BIM; both

232 The rate of response in group 2 was noninferior to that of group 1.

233 The AUC was noninferior to that of human retinal specialists.

234 The EFS for SR patients in AAML0631 was noninferior to that of patients in the AIDA 0493 his

235 The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.

236 sis found that the efficacy of isavuconazole was noninferior to that of voriconazole.

237 at outcomes of patients followed in the TMVC are noninferior to the CIC.

238 onths; 0, 6, 12 months; or 0, 12, 24 months) are noninferior to the standard schedule at >2 years aft

239 three lower-dose alternatives were found to be noninferior to the routine-dose FBP.

240 We hypothesized that VO training would be noninferior to the VSI approach with respect to chest

241 Assessment of LV function with SSIR at 3.0 T is noninferior to the standard of reference irrespective

242 operative urine output target of 0.2 mL/kg/h is noninferior to the standard target of 0.5 mL/kg/h and

243 95% confidence interval: 0.8%, 5.7%), which was noninferior to the 2.1% (13 of 626 patients; 95% con

244 the 62.1% treatment success in the CD group was noninferior to the 71.0% in the iHT group (differenc

245 PA by LTA for prasugrel 5 mg in LBW patients was noninferior to the 75th percentile for prasugrel 10

246 The MGI was noninferior to the BGI in lowering IOP.

247 The MGI was noninferior to the BGI when comparing postoperative

248 he thin-strut sirolimus-eluting Orsiro stent was noninferior to the biolimus-eluting Nobori stent in

249 ion in the extended-release naltrexone group was noninferior to the buprenorphine-naloxone group (dif

250 he every 12 weeks regimen of zoledronic acid was noninferior to the every 4 weeks regimen for the pro

251 and showed a "simplified" artesunate regimen was noninferior to the existing World Health Organizatio

252 The rate of MACCE (7.3%) was noninferior to the performance goal (18.3%, pnoninfe

253 The respiratory polygraphy protocol was noninferior to the polysomnography protocol based on

254 A(H1N1) during 2012-2013 (the HD formulation was noninferior to the SD formulation for influenza A[H1

255 tients with coronary artery disease, the EES was noninferior to the SES at 9 months.

256 The drug-coated balloon was noninferior to the standard balloon with respect to

257 QIV was noninferior to the TIVs for shared strains (A/H3N2 a

258 indication for pacing, the subcutaneous ICD was noninferior to the transvenous ICD with respect to d

259 The use of high-flow nasal cannulae was noninferior to the use of nasal CPAP, with treatment

260 BP, 0.908; SAFIRE 3, 0.935; SAFIRE 4, 0.924) were noninferior to the mean AUC with full-dose FBP scan

261 1 and 2 each had high rates of SVR12, which were noninferior to the reported rate of response to the

262 at indicate that the DTG-containing regimens were noninferior to the standard-care regimen.

263 shown that antibody responses after 2 doses are noninferior to those after 3 doses, suggesting that

264 -16 and HPV-18 one month after the last dose were noninferior to those among young women who received

265 Diagnoses from WSI were noninferior to those from TM.

266 Antibody responses to HPV-6, 11, 16, and 18 were noninferior to those generated by the qHPV vaccine.

267 LBN 0.024% QD in the evening was noninferior to timolol 0.5% BID over 3 months of tre

268 ), a first-in-class IOP-lowering medication, was noninferior to timolol BID and was associated with t

269 aseline intraocular pressure (P < .001), and was noninferior to timolol in the per-protocol populatio

270 Both dose strengths of bimatoprost implant were noninferior to timolol in IOP lowering after each a

271 -cell depletion with rituximab may therefore be noninferior to treatment with cyclosporine for induci

272 lin for chest-indrawing pneumonia for 3 days was noninferior to treatment for 5 days.

273 A single dose of oritavancin was noninferior to twice-daily vancomycin administered f

274 TC was noninferior to UC on all primary outcomes.

275 sing amoxicillin to treat this condition may be noninferior to using amoxicillin.

276 It has been found to be noninferior to vancomycin; however, its cost-effectiv

277 TARGET demonstrated that ceftobiprole is noninferior to vancomycin/aztreonam in the treatment

278 In 2 phase 3 clinical trials, telavancin was noninferior to vancomycin in patients with HAP due t

279 lary blood samples collected by finger-prick was noninferior to venous blood collected in PAXgene tub

280 taneous left atrial appendage closure (LAAC) is noninferior to vitamin K antagonists (VKAs) for preve

281 Direct oral anticoagulants are noninferior to warfarin with regard to efficacy and

282 aroxaban, apixaban, dabigatran, and edoxaban-is noninferior to warfarin (absolute rate of recurrent V

283 Rivaroxaban is noninferior to warfarin for preventing stroke in atri

284 In this trial, LAA occlusion was noninferior to warfarin for ischemic stroke preventi

285 s major bleeding; and rivaroxaban 20 mg Q.D. was noninferior to warfarin for stroke and systemic embo

286 dage closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atr

287 NVAF), left atrial appendage (LAA) occlusion was noninferior to warfarin for stroke prevention, but a

288 Atrial Fibrillation (ROCKET AF), rivaroxaban was noninferior to warfarin for the prevention of stroke

289 superior and dabigatran etexilate 110 mg BID was noninferior to warfarin in preventing stroke and sys

290 rction 48), the factor Xa inhibitor edoxaban was noninferior to warfarin in preventing stroke or syst

291 arge randomized, clinical trial, rivaroxaban was noninferior to warfarin in preventing stroke or syst

292 Dabigatran etexilate 110 mg BID was noninferior to warfarin in reducing stroke and syste

293 The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Dail

294 e (Boston Scientific, Natick, Massachusetts) was noninferior to warfarin therapy.

295 nd a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin with respect to the mean tim

296 Edoxaban was noninferior to warfarin with respect to the primary

297 actor Xa inhibitor with 50% renal clearance, was noninferior to well-managed warfarin for stroke or s

298 O-SES was noninferior to X-EES for the primary end point (0.10

299 zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 w

300 amine whether zoledronic acid every 12 weeks was noninferior to zoledronic acid every 4 weeks in pati